arrow
D

Dolores Hambardzumyan

Tisch Cancer Institute
H指数:53
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reply to “Ascertainment of overall survival and the proposed molecular grading tier in IDH-mutant astrocytoma”

回复“IDH突变型星形细胞瘤的整体生存评估及提出的分子分级分层”

2026-09-030
PRE
Validation of proposed cIMPACT-NOW update 12 molecular grading criteria for IDH-mutant astrocytoma

验证针对IDH突变型星形细胞瘤提出的cIMPACT-NOW更新12分子分级标准

2026-07-220
OAAI
Aquaporin-4 loss in astrocytes drives glioblastoma-associated cerebral edema and alters the tumor immune microenvironment

水通道蛋白-4在星形胶质细胞中的丢失驱动胶质母细胞瘤相关的脑水肿并改变肿瘤免疫微环境

2025-11-010
OAAI
Enhancing 5-ALA Photodynamic Therapy with MEK Inhibition for Targeted Treatment of H3K27-Mutant Diffuse Midline Glioma

增强5-ALA光动力疗法与MEK抑制联合治疗H3K27突变型中线弥漫性胶质瘤

2025-11-010
OAAI
DECODING THE SPATIAL ARCHITECTURE OF INTEGRATED ELECTROPHYSIOLOGICAL AND TRANSCRIPTOMIC DIVERSITY IN MALIGNANT BRAIN TUMORS

解码恶性脑肿瘤中整合电生理和转录组多样性空间架构

2025-11-010
OAAI
EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma

EGFR alteration是IDH-mutant astrocytoma的不良预后因素。

2025-08-190
OAAI
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon

弥漫性半球神经胶质瘤,H3 G34-mutant疾病发展,DNA修复,微环境和治疗方法的综述

2025-08-140
OAAI
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma

BRAF/MEK抑制诱导BRAFV600E突变型胶质瘤细胞状态转变,增强免疫检查点敏感性

2025-06-120
OA
Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations
IMMUNITY
IF26.3
2024-11-010
PRE